Investigating the Effect of Whole-fruit Coffee Extract on Exercise Performance (PACE)

Caffeine is a widely used efficacious supplement by both the general public, and athletes, with the goal of improving performance. The effects of caffeine alone are well known, but it is not clear whether a multi-ingredient supplement (containing both caffeine and polyphenols) can affect exercise performance.

This study aims to determine if a low dose of caffeine, in the form of a whole-fruit coffee extract also containing polyphenols, can improve exercise performance compared to a placebo condition, with a secondary objective of identifying if this supplement can improve post exercise refuelling (glycogen resynthesis).

Participants will consume either the supplement or a placebo before engaging in an exercise protocol. Muscle biopsies will then be obtained so as to measure subsequent glycogen resynthesis, with multiple blood samples being taken through the day. The following morning another biopsy will be taken before the exercise protocol will be repeated.

This research will inform us of the efficacy of caffeine and polyphenols on improving exercise performance.

Study Overview

• Status: Completed
• Conditions: Caffine and Endurance Performance
• Intervention / Treatment: Dietary supplement: Placebo; Dietary supplement: CoffeeBerry Supplement

• Study Type: Interventional
• Enrollment (Actual): 14
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • Exeter, United Kingdom, EX1 2LU
    • University of Exeter
  • Devon
    • Exeter, Devon, United Kingdom, EX1 2LU
      • Sport & Health Sciences University of Exeter

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Exclusion criteria:

• Allergy to Lidocaine
• Exclusion critera
• Any diagnosed metabolic health condition
• Pregnant
• Non-habitual caffeine intake
• Smoker
• No endurance training
• Diagnosed Cardiovascular disease
• Beta-Blockers
• Recent history of musculoskeletal injury

Inclusion criteria:

• Age 18-40
• Heathy
• Highly trained endurance athletes (V̇O2max: males >55 and females >50 mL⋅kg bm-1⋅min-1)
• Both males and females are allowed to participate. If females are on the oral contraceptive pill they are to be tested on consecutive weeks. If they are not on the oral contraceptive pill, then female subjects are to be tested every 4 weeks, at the same point of their menstrual cycle.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Dietary supplement: Placebo; Placebo
Experimental: CoffeeBerry Supplement; Caffeine and polyphenol supplement	Dietary supplement: CoffeeBerry Supplement; A Coffeeberry supplement containing 200mg Caffeine and 14mg polyphenols, manufactured by FutureCeuticals Inc.,

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exercise performance	Amount of work completed in 15 minutes	15 Minitues

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Glycogen Resynthesis	The diffrence in glycogen within the muscle between two time points	24 Hours
Alertness	10 cm visual analog scale (Ranging from Not Alert to Extremly Alert)	1 Minitue
Motivation	10 cm visual analog scale (Ranging from Not motivated to Extremly motivated)	1 Minitue
Rate of perceived exertion	Validated Borg scale (6-20 Arbitrary units)	1 Minitue
Urine osmolarity	The hydration status of the individual measured in mOsmo|/kg	24 Hours
GI comfort	10 cm visual analog scale (Ranging from No discomfort to Extreme discomfort)	1 Minitue

Collaborators and Investigators

• Sponsor: University of Exeter
• Collaborators: VDF FutureCeuticals Inc.

Study record dates

Study Major Dates

• Study Start (Actual): February 4, 2022
• Primary Completion (Actual): January 25, 2023
• Study Completion (Actual): January 25, 2023

Study Registration Dates

• First Submitted: January 10, 2022
• First Submitted That Met QC Criteria: June 1, 2022
• First Posted (Actual): June 3, 2022

Study Record Updates

• Last Update Posted (Actual): March 22, 2023
• Last Update Submitted That Met QC Criteria: March 21, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: 2021-10-20-B-05

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No